1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). The NCI SBIR/STTR program provides non-dilutive funding and commercialization support to small businesses developing innovative cancer-related technologies, including immunotherapies. It accelerates the translation of innovative immunotherapy discoveries into clinical applications.
The program supports a broad spectrum of technology readiness, from proof-of-concept studies to clinical trials.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI), National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NCI SBIR/STTR Omnibus Grant Solicitations - NCI The SBIR and STTR programs were reauthorized on April 13, 2026. Currently, NIH has no active SBIR or STTR Notices of Funding Opportunity (NOFOs). Future NOFOs are forecasted at Grants.
gov prior to opening for applications. The next standard receipt date is September 5, 2026. NCI SBIR/STTR Omnibus Grant Solicitations The Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas.
U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics.
Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms continue to be eligible to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.
Omnibus Solicitation Opportunities This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
SBIR Program: PA-24-245 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 SBIR Program: PA-24-246: (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-247 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-248 (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 Online HTML Application Guide SF424 (R&R) Application Guide for SBIR/STTR Grant Applications (Version H) Annotated SF424 SBIR/STTR Form Set NIH Matchmaker - Use NIH Matchmaker to conduct keyword searches on a particular topic area to identify NIH Institutes or Centers (ICs) that have previously funded research area.
Based on current listing details, eligibility includes: Small businesses with an investigator-defined scope within the mission of NIH, focusing on research areas such as therapeutics, diagnostics, imaging technologies, and devices for cancer therapy. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $300,000 to $4.5 million Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity invites investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically GLP-1 or dual GLP-1/GIP-1 receptor agonists, impact cancer risk. The focus includes reported effects on thyroid, prostate, and other cancer risks. The NOFO also aims to attract scientists from other fields to study incretin mimetic effects on cancer biology.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). Supports the development of biomarkers or clinical outcomes derived from digital health technology for remote monitoring in clinical trials.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.